Having verified that hIL15-ABD is superior to hIL15 in inhibiting tumor growth and regulating anti-cancer immunity, we investigated the anticancer efficacy and immune response induction of hIL15-ABD combined with anti-PD-L1 in both CC and melanoma models. Here, CD274 is linked to melanoma.